Cipla on Monday announced the closure of inspection by the US health regulator at its Patalganga manufacturing facility in Maharashtra.
"Following the inspection by the United States Food and Drug Administration (USFDA) at the Patalganga manufacturing facility of the company from November 4, 2019 to November 13, 2019, the company has received the Establishment Inspection Report (EIR), indicating closure of the inspection," the homegrown pharma major said in a filing to the BSE.
Shares of Cipla were trading 0.40 per cent lower at Rs 478.35 apiece on the BSE in the morning trade.
Disclaimer: No Business Standard Journalist was involved in creation of this content
